A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/21/2004	US6833389 Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful in the treatment of Chlamydia pneumoniae infections
12/21/2004	US6833387 Chemical compounds
12/21/2004	US6833383 Methods for treating patients suffering from drug dependencies which lead to plasma melatonin deficiencies
12/21/2004	US6833382 Streptogramins and method for preparing same by mutasynthesis
12/21/2004	US6833381 TNF-α inhibitors
12/21/2004	US6833380 Compounds that modulate PPAR activity and methods of preparation
12/21/2004	US6833379 As diuretic agent
12/21/2004	US6833378 Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders.
12/21/2004	US6833376 5-aminoalkyl and 5-aminocarbonyl substituted indole derivative useful for treatment of psychosis in a mammal
12/21/2004	US6833375 As inhibitors of the retinoic acid-metabolism, as drugs
12/21/2004	US6833374 Dihydropyrazolo[3,4-d]thieno[2,3-B]pyridinone inhibitors of B7-1
12/21/2004	US6833373 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
12/21/2004	US6833372 A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups
12/21/2004	US6833371 Contacting cell with a sodium channel-inhibiting amount of a compound comprising a pyrazolopyrimidine moiety for decreasing ion flow through a voltage-dependent sodium channel in a cell
12/21/2004	US6833369 Treatment of ocular neovascular diseases, neovascular glaucoma, diabetic retinopathy,
12/21/2004	US6833368 Tackykinin antagonist
12/21/2004	US6833367 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
12/21/2004	US6833366 Alpha v beta 3 and/or 5 integrin antagonists; reduced side effects
12/21/2004	US6833365 Such as 5-propionyl-6-cyclopentylsulfanylmethyl doxycycline; for treating diarrhea in immunodeficient individuals
12/21/2004	US6833364 Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine
12/21/2004	US6833363 N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
12/21/2004	US6833362 Method and composition for the accelerated in vivo removal of ethanol
12/21/2004	US6833360 Reacting pseudoephedrine with tannins at a temperature of about 50 to about 115 degrees C.; sustained release nasal decongestant
12/21/2004	US6833353 Inhibiting matrix metalloprotease (MMP) production using such as tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxy-ascomycin
12/21/2004	US6833348 Inhibiting apoptosis mediated by CD3 T-cell receptor or Fas/Fas-L systems; stimulating lymphocyte activity
12/21/2004	US6833264 Hyaluronan synthase gene and uses therof
12/21/2004	US6833142 Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
12/21/2004	US6833140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
12/21/2004	US6833139 Composition and method for the treatment of anorectal disorders
12/21/2004	US6833138 Plaster containing felbinac
12/21/2004	US6833130 Recombinant microorganisms expressing an oligosaccharide receptor mimic
12/21/2004	CA2317604C Matrix metalloprotease inhibitors
12/21/2004	CA2252071C Anti-caries oral compositions
12/21/2004	CA2241904C Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
12/21/2004	CA2227241C Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
12/21/2004	CA2167926C Use of benzydamine in the treatment of pathological conditions caused by tnf
12/21/2004	CA2140649C Hybrid oligonucleotide phosphorothioates
12/21/2004	CA2134674C Gaba and l-glutamic acid analogs for antiseizure treatment
12/21/2004	CA2079968C Mono-fluorinated derivatives of n-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
12/16/2004	WO2004109768A2 Methods and intermediates for the synthesis of dipyrrin-substituted porphyrinic macrocycles
12/16/2004	WO2004109390A1 Laser projector
12/16/2004	WO2004109290A2 Methods for identifying modulators of kinesin activity
12/16/2004	WO2004108960A2 Methods for predicting drug efficacy in patients afflicted with hypertension
12/16/2004	WO2004108941A1 Biologically active oils
12/16/2004	WO2004108914A1 Sars coronaviruses 3cl protease 3d-structure model and anti-sars medicines
12/16/2004	WO2004108892A2 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
12/16/2004	WO2004108867A2 Cyclohexene carboamides and carbothioamides
12/16/2004	WO2004108746A2 11-12 bicyclic erythromycin derivatives
12/16/2004	WO2004108745A2 11-12 bicyclic erythromycin derivatives
12/16/2004	WO2004108733A1 Beta-lactamase inhibitor prodrug
12/16/2004	WO2004108731A1 Beta-strand mimetics and method relating thereto
12/16/2004	WO2004108730A1 1h-imidazo`4,5-d!pyridazines as dpp-iv inhibitors for the treatment of niddm
12/16/2004	WO2004108729A1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF
12/16/2004	WO2004108728A1 Cannabinoid receptor ligands and uses thereof
12/16/2004	WO2004108724A1 Tricyclic compound
12/16/2004	WO2004108715A1 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
12/16/2004	WO2004108713A1 Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
12/16/2004	WO2004108712A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/16/2004	WO2004108709A1 Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents
12/16/2004	WO2004108706A1 Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
12/16/2004	WO2004108705A1 3-fluoro-piperidines as nmda/nr2b antagonists
12/16/2004	WO2004108700A1 Processes for preparation of polymorphic forms of desloratadine
12/16/2004	WO2004108698A1 Process for producing cyclic lactic acid oligomer having two-fold polymerization degree
12/16/2004	WO2004108695A1 Anti-leishmania agent
12/16/2004	WO2004108689A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/16/2004	WO2004108688A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/16/2004	WO2004108687A2 Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection
12/16/2004	WO2004108684A1 Novel azole derivative having antifungal activity
12/16/2004	WO2004108682A2 Tetrahydroisoquinolines as antagonists of the 5ht1b receptor
12/16/2004	WO2004108681A1 Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
12/16/2004	WO2004108676A1 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists
12/16/2004	WO2004108675A1 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
12/16/2004	WO2004108674A1 Amino alcohol derivative, medicinal composition containing the same, and uses of these
12/16/2004	WO2004108673A2 Inhibitors of papilloma virus
12/16/2004	WO2004108672A1 Isoindolin-1-one compounds as kinase inhibitors
12/16/2004	WO2004108670A1 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
12/16/2004	WO2004108666A2 Neuroprotective benzoate and benzamide compounds
12/16/2004	WO2004108664A2 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
12/16/2004	WO2004108659A1 New method for synthesizing ceramide-type compounds
12/16/2004	WO2004108654A1 Chain lactic acid oligomer derivative and process for producing the same
12/16/2004	WO2004108645A1 Method for the treatment or prevention of lower urinary tract symptoms
12/16/2004	WO2004108635A2 Mixed zeaxanthin ester concentrate and uses thereof
12/16/2004	WO2004108266A1 Micropellets, method for the production thereof, and use thereof
12/16/2004	WO2004108215A1 Piperidinyl prostaglandin e analogs
12/16/2004	WO2004108163A1 Method for preparing powder exhibiting low susceptibility to electrification
12/16/2004	WO2004108162A2 Controlled release pharmaceutical composition
12/16/2004	WO2004108161A1 Solid pharmaceutical preparation
12/16/2004	WO2004108160A1 Osteogenesis-promotion enhancer and method of screening the same
12/16/2004	WO2004108153A1 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
12/16/2004	WO2004108151A1 Inhibition of sars coronavirus infection with clinically approved antiviral drugs
12/16/2004	WO2004108148A1 Processes for making caralluma extracts and uses
12/16/2004	WO2004108143A1 Composition consisting of alkane dicarboxylic acids and a pharmaceutically active ingredient
12/16/2004	WO2004108142A2 Inhibitors of tip-1 for treatment tissue damage
12/16/2004	WO2004108141A2 Bach-o-protein coupled receptor releated methods
12/16/2004	WO2004108140A1 Composition for inhibiting differentiation or growth of fat cells
12/16/2004	WO2004108139A2 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
12/16/2004	WO2004108138A1 Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
12/16/2004	WO2004108137A1 A method of treating an anxiety disorder
12/16/2004	WO2004108136A1 Triazolo `1 , 5-a!pyrimidines and their use in medicine
12/16/2004	WO2004108135A1 Composition and method for treating macular disorders

1 ... 4854 4855 4856 4857 4858 4859 4860 4861 4862 4863 4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 ... 7860